List of Excipients in Branded Drug AMYVID

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Eli Lilly and Company	AMYVID	florbetapir f 18	0002-1200	ALCOHOL	2027-04-30
Eli Lilly and Company	AMYVID	florbetapir f 18	0002-1200	SODIUM ASCORBATE	2027-04-30
Eli Lilly and Company	AMYVID	florbetapir f 18	0002-1200	SODIUM CHLORIDE	2027-04-30

AMYVID Excipient Strategy and Commercial Opportunities in Florbetapir F 18 PET Imaging

Last updated: September 6, 2026

AMYVID is a sterile intravenous positron-emission tomography (PET) diagnostic containing florbetapir F 18, a radioactive ligand used to estimate beta-amyloid neuritic plaque density in the brains of adults with cognitive impairment. Its excipient strategy is deliberately narrow: aqueous isotonic delivery, low particulate burden, minimal chemical complexity, and compatibility with short-lived radioactive drug production.

The most credible commercial opportunities are not conventional excipient substitution. They are linked to radiopharmacy manufacturing, sterile ready-to-use presentation, supply-chain reliability, PET-center workflow, and future florbetapir or amyloid-imaging products.

What is AMYVID and how is it formulated?

AMYVID, also known as florbetapir F 18 injection, was approved by the U.S. Food and Drug Administration in April 2012 under NDA 202008. Eli Lilly and Company developed the product through its Avid Radiopharmaceuticals business. The product is administered intravenously for PET imaging of the brain. [1,2]

Attribute	AMYVID profile
Active ingredient	Florbetapir F 18
Dosage form	Sterile intravenous injection
Route	Intravenous
Diagnostic use	PET estimation of beta-amyloid neuritic plaque density
Radionuclide	Fluorine-18
Physical half-life	Approximately 110 minutes
FDA approval	April 6, 2012
Application	NDA 202008
Sponsor	Eli Lilly and Company
Administration	Intravenous bolus, followed by saline flush
Key formulation objective	Rapid, sterile delivery with low excipient load

The FDA prescribing information identifies sodium chloride, ethanol and water for injection as formulation components. The product is supplied as a clear, colorless solution. Because fluorine-18 decays rapidly, the commercial product is produced and released through a qualified radiopharmacy or manufacturing network rather than through conventional long-term inventory distribution. [1]

What excipients are used in AMYVID?

AMYVID uses a simple aqueous formulation. The principal excipient functions are isotonicity adjustment, solvent support and injectable-volume control.

Excipient or component	Likely function	Commercial relevance
Sodium chloride	Isotonicity and injection compatibility	Commodity ingredient; low differentiation
Ethanol	Solvent and formulation-process support	Quality-control and residual-solvent relevance
Water for injection	Primary vehicle	Requires sterile pharmaceutical-grade supply
Florbetapir F 18	Diagnostic active ingredient	Dominant technical and regulatory constraint

The formulation does not rely on a complex lipid system, polymeric carrier, sustained-release matrix, preservative system or particulate delivery platform. That limits the opportunity to create a differentiated “AMYVID-like” excipient product through ordinary formulation changes.

Why is the excipient load intentionally low?

A low-excipient formulation is appropriate for a short-lived injectable radiopharmaceutical because:

1. The product is administered in a small volume.
2. The active ingredient is used at tracer levels.
3. The drug is generally prepared close to the imaging site.
4. Each additional excipient creates potential risks involving radiolysis, sterility, extractables, toxicology and product specifications.
5. PET radiopharmaceuticals require tight control of radiochemical purity, chemical purity and particulate matter.

Ethanol concentration, pH, osmolality, radiochemical purity and radionuclidic identity can affect product performance and patient exposure. Any proposed excipient change would require analytical comparability and, depending on the regulatory pathway, additional nonclinical or clinical support.

What excipient strategy is commercially viable for AMYVID?

The strongest strategy is a risk-reduction strategy rather than a molecule-replacement strategy.

1. Pharmaceutical-grade ethanol supply

Ethanol is a technically manageable but important component. Suppliers can compete through:

• Sterile or low-bioburden pharmaceutical-grade material
• Consistent water content
• Low aldehyde and impurity profiles
• Container-closure compatibility
• Documentation supporting radiopharmaceutical manufacturing
• Reliable small-batch and regional supply

The opportunity is modest because ethanol is widely available. The value lies in qualification, consistency and supply continuity rather than high unit margins.

2. Sterile water and sodium chloride systems

Sterile water for injection and sodium chloride are established products with limited formulation differentiation. Suppliers can still create value through:

• Ready-to-use sterile containers
• Small-volume presentations
• Low-extractables packaging
• Radiopharmacy-compatible transfer systems
• Validated cold-chain or controlled-room-temperature logistics
• Regional distribution near PET production sites

The commercial case is stronger for an integrated sterile component platform than for a standalone commodity excipient.

3. Radiopharmaceutical manufacturing consumables

The most attractive adjacent market involves materials used to manufacture, dispense and release AMYVID-type products:

• Sterile single-use vials
• Low-binding syringes
• Shielded dose containers
• Septa and closures with low extractables
• Sterile filters
• Tubing sets and transfer assemblies
• Automated dispensing consumables
• Radiation-compatible labels and packaging

These materials can reduce operator exposure, improve dose accuracy and shorten release workflows. Their value is operational and regulatory rather than pharmacological.

4. Formulation support for radiolysis control

Radiolysis can generate impurities during production, transport and administration. Antioxidants, buffers or stabilizers may be considered in other fluorine-18 products, but adding them to AMYVID would require a clear benefit because new components can alter:

• Radiochemical stability
• Binding characteristics
• PET image quality
• Toxicological profile
• pH and osmolality
• Sterility and release testing

A supplier proposing a stabilizer must demonstrate that the material does not create new radioactive or nonradioactive impurities. This is a high technical barrier for a low-dose diagnostic product.

What patents protect AMYVID and its formulation?

The relevant intellectual-property estate historically has included several layers:

Protection category	Relevance to AMYVID
Florbetapir chemistry	Protects the labeled ligand or precursor chemistry
Fluorine-18 radiolabeling methods	Protects production or synthesis processes
Amyloid imaging methods	Protects clinical interpretation or use of PET imaging
Manufacturing methods	May cover precursor handling, purification or quality control
Formulation claims	Potentially cover injectable composition or stability
Excipient claims	Likely narrower and less commercially central

The commercial barrier is unlikely to be an excipient patent by itself. The more important barriers are the active pharmaceutical ingredient, radiolabeling know-how, validated production processes, FDA-approved manufacturing controls and access to PET distribution networks.

Public FDA regulatory records and the Orange Book should be reviewed for current listed patents and exclusivity status before a launch or licensing decision. The Orange Book is the controlling source for listed patents and patent certifications associated with an approved small-molecule drug product. [3]

When did AMYVID lose regulatory exclusivity?

AMYVID's principal FDA approval occurred in 2012. New chemical entity exclusivity for an eligible small-molecule product generally lasts five years, subject to statutory exceptions and paragraph IV timing. That period would have ended approximately in 2017 unless another regulatory exclusivity applied. [4]

The product's commercial protection therefore depends more heavily on patents, manufacturing capability and market access than on remaining FDA exclusivity.

Milestone	Approximate date or status
FDA approval	April 2012
Five-year NCE exclusivity window	Generally through approximately 2017
Current exclusivity significance	Limited compared with manufacturing and patent barriers
Current generic pathway	505(j) may be technically difficult because of radioactive manufacturing and product-specific requirements
Biosimilar pathway	Not applicable; AMYVID is a small-molecule radiopharmaceutical

Are there paragraph IV challenges to AMYVID?

A paragraph IV challenge is legally possible for an approved small-molecule product if an applicant submits an ANDA that certifies listed patents are invalid, unenforceable or not infringed. The practical feasibility for AMYVID is less straightforward than for a conventional tablet or injectable.

An AMYVID-type ANDA would need to address:

• Florbetapir F 18 identity and purity
• Precursor and radiolabeling controls
• Radionuclidic purity
• Radiochemical purity
• Sterility and endotoxin limits
• Dose calibration and decay correction
• Container closure
• Stability over the short usable period
• PET image interpretation and product performance

A conventional generic manufacturer cannot rely only on chemical sameness. It must operate or contract a compliant radiopharmaceutical production network. The absence of a widely visible paragraph IV dispute does not eliminate generic risk; it indicates that technical and commercial barriers may be more important than litigation economics.

What formulation patents could protect an AMYVID follow-on?

A follow-on formulation could seek protection for a specific combination involving:

• Stabilizer concentration ranges
• Ethanol and saline ratios
• pH control
• Reduced radiolysis
• Extended usable time after synthesis
• Improved container compatibility
• Low-surface-adsorption delivery systems
• Pre-filled or unit-dose syringe presentations
• Automated dispensing configurations

The strongest claim strategy would connect the formulation to a measurable technical result, such as improved radiochemical stability or reduced impurity formation. A broad claim covering saline, ethanol and water would face substantial validity and obviousness pressure because these components are conventional injectable excipients.

A formulation patent is stronger when it protects a defined manufacturing problem that is difficult to solve in a short-lived radiopharmaceutical. Examples include maintaining radiochemical purity during a validated distribution interval or improving dose uniformity in an automated dispensing system.

What generic entry risks exist for AMYVID?

Technical entry risk

The 110-minute half-life of fluorine-18 creates a narrow manufacturing and delivery window. A commercial entrant needs production sites close to PET centers or a highly reliable regional distribution model.

Regulatory entry risk

The product must meet radiopharmaceutical-specific controls. Small differences in precursor quality, synthesis conditions, purification or container materials can change the impurity profile.

Commercial entry risk

PET centers generally value dependable delivery, predictable activity at administration time, scanner compatibility and radiopharmacist support. Price alone may not displace an established supplier.

Litigation risk

The main patent disputes would likely concern synthesis, precursor chemistry, imaging methods or manufacturing processes rather than simple excipient composition.

Reimbursement risk

Demand depends on physician adoption, payer coverage, PET capacity and the clinical role of amyloid imaging. FDA approval does not guarantee broad reimbursement.

How does AMYVID compare with competing amyloid PET tracers?

AMYVID competes with other FDA-approved amyloid PET agents, including VIZAMYL, which contains flutemetamol F 18, and NEURACEQ, which contains florbetaben F 18. These products share a broad commercial model but differ in ligand chemistry, imaging protocols, manufacturing processes and distribution infrastructure. [5,6]

Product	Active ingredient	Radionuclide	Commercial comparison
AMYVID	Florbetapir F 18	Fluorine-18	Established amyloid PET product with simple aqueous formulation
VIZAMYL	Flutemetamol F 18	Fluorine-18	Competes for PET-center capacity and diagnostic workflow
NEURACEQ	Florbetaben F 18	Fluorine-18	Competes on availability, interpretation and site economics

Excipient opportunities are similar across the category. Differentiation is more likely to arise from manufacturing efficiency, dose logistics, distribution reach, and image-interpretation support than from a new vehicle.

What licensing opportunities exist around AMYVID?

Potential licensing structures include:

1. Regional manufacturing licenses for florbetapir F 18.
2. Rights to validated precursor or radiolabeling technology.
3. Contract manufacturing agreements with hospital-based cyclotron networks.
4. Supply agreements for sterile vials, syringes and shielding systems.
5. Technology licenses for automated dispensing and dose-management systems.
6. Co-development of next-generation amyloid or tau PET tracers.
7. Distribution partnerships that improve same-day delivery to PET centers.

An excipient company is unlikely to obtain meaningful value from licensing sodium chloride or water for injection alone. A stronger proposition combines excipients with validated sterile packaging, radiation-compatible components, quality-control methods and regional supply.

What FDA and Orange Book status matters for commercial planning?

AMYVID is an FDA-approved small-molecule radiopharmaceutical under NDA 202008. Regulatory planning should distinguish among:

• FDA approval of the reference product
• Orange Book-listed patents
• FDA exclusivity periods
• Current marketing status
• Manufacturing-site approvals
• Drug Master Files for excipients or components
• ANDA eligibility and pharmaceutical equivalence
• State and federal radiopharmacy requirements

A supplier that changes an excipient or container component may need to support a supplement to the approved application rather than obtain an entirely new drug approval. The regulatory burden depends on whether the change affects identity, strength, quality, purity, stability, sterility, radiochemical performance or clinical use.

What is the revenue exposure and market opportunity?

Eli Lilly does not generally report AMYVID revenue as a separately disclosed public segment. Product-level revenue, volume and margin estimates therefore cannot be stated reliably from public company reporting.

The broader opportunity is tied to the growth of amyloid PET imaging and the clinical use of anti-amyloid therapies, which can increase demand for biomarker confirmation. The opportunity is constrained by PET scanner availability, radiopharmacy distribution, reimbursement, specialist interpretation and the need for trained readers.

For excipient and packaging suppliers, the addressable value is smaller than the diagnostic drug market but can be more defensible when tied to qualified supply chains. The highest-value targets are:

• Radiopharmacy networks
• Contract manufacturing organizations
• PET-center operators
• Automated dose-dispensing companies
• Sterile packaging manufacturers
• Suppliers of validated precursor and synthesis materials

How strong is the AMYVID patent estate?

The patent estate is strongest where it protects proprietary ligand chemistry, radiolabeling processes or validated manufacturing methods. It is weaker for basic excipients because saline, ethanol and water for injection are standard pharmaceutical materials.

Patent layer	Relative strength
Florbetapir active-agent chemistry	Potentially high, depending on claim scope and expiration
Radiolabeling process	Moderate to high if process-specific and difficult to design around
Imaging method	Moderate, subject to claim scope and enforceability
Basic saline-ethanol formulation	Low to moderate
Sterile packaging configuration	Moderate if tied to technical performance
Generic excipient supply	Low

A freedom-to-operate review should cover U.S. and foreign patents, prosecution history, terminal disclaimers, continuations, reissues and Orange Book listings. Patent expiration should be determined patent by patent rather than inferred from the 2012 approval date.

Key Takeaways

• AMYVID uses a simple aqueous injectable formulation based on florbetapir F 18, sodium chloride, ethanol and water for injection.
• Excipient substitution is a limited opportunity because the formulation is already simple and the product is a short-lived radiopharmaceutical.
• The best commercial opportunities are in sterile packaging, radiopharmacy consumables, automated dispensing and qualified regional supply.
• Generic entry is technically harder than for a conventional injectable because fluorine-18 production, decay timing and radiochemical quality must be controlled.
• The most important intellectual-property risks concern florbetapir chemistry, radiolabeling and manufacturing methods, not commodity excipients.
• Amyloid PET competition includes VIZAMYL and NEURACEQ, making delivery reliability and PET-center workflow important commercial differentiators.
• Product-level AMYVID revenue is not separately disclosed by Eli Lilly.
• A formulation patent is most defensible when it claims a measurable improvement in radiochemical stability, impurity control or dose-delivery performance.

FAQs

Can sodium chloride be replaced in an AMYVID-type formulation?

Only after demonstrating equivalent isotonicity, sterility, compatibility, stability and radiochemical performance. A replacement would require regulatory assessment and may require a supplement to the approved application.

Does AMYVID need a preservative?

A preservative is generally undesirable in a small-volume intravenous radiopharmaceutical unless it provides a defined benefit. Preservatives can introduce toxicity, compatibility and radiolysis concerns.

Can AMYVID be manufactured as a conventional generic injectable?

The product could theoretically be pursued through an abbreviated pathway, but the applicant would need validated fluorine-18 synthesis, radiochemical testing, sterile manufacturing and time-sensitive distribution. Those requirements make the pathway more specialized than a standard generic injection.

What is the most valuable excipient-related patent opportunity for florbetapir F 18?

A patent claiming a defined stabilizing or packaging system that measurably extends radiochemical purity or improves dose accuracy is more commercially credible than a broad claim to saline, ethanol and water.

Can a hospital pharmacy compound an AMYVID substitute?

Routine hospital compounding does not create an authorized substitute for the FDA-approved product. Florbetapir F 18 production requires appropriate radiopharmaceutical facilities, qualified personnel, validated processes and compliance with applicable FDA and state requirements.

References

1. U.S. Food and Drug Administration. (2012). Amyvid (florbetapir F 18 injection) prescribing information. Eli Lilly and Company.

2. U.S. Food and Drug Administration. (2012). FDA approves first radioactive diagnostic agent for detection of beta-amyloid plaques in the brains of patients being evaluated for cognitive decline. FDA.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. U.S. Code, 21 U.S.C. § 355. (2024). New drug applications and abbreviated applications.

5. U.S. Food and Drug Administration. (2013). Vizamyl (flutemetamol F 18 injection) prescribing information. FDA.

6. U.S. Food and Drug Administration. (2014). Neuraceq (florbetaben F 18 injection) prescribing information. FDA.